Socransky S S, Haffajee A D. Evidence of bacterial etiology: a historical perspective[J]. Periodontology 2000, 1994, 5(1): 7-25.
[3]
Costerton W, Veeh R, Shirtliff M, et al. The application of biofilm science to the study and control of chronic bacterial infections[J].J Clin Inves,2003,112(10):1466.
[4]
Li L X, Wang Q X, Song Z W, et al. Introduction of Biofilm with an Analysis of its Typical Process Advanced Materials Research[J]. Trans Tech Publications, 2013, 850: 1234-1237.
[5]
David H, Bettina A, Rubén L, et al. Antimicrobial therapy in periodontitis: the use of systemic antimicrobials against the subgingival biofilm.[J]. J Clin Periodonto, 2008, 35(Supplement s8):45-66.
[6]
Walker T S, Tomlin K L, Worthen G S, et al. Enhanced Pseudomonas aeruginosa biofilm development mediated by human neutrophils[J]. Infection and immunity, 2005, 73(6): 3693-3701.
[7]
Yu N, Oortgiesen D W, Bronckers A L J J, et al. J Clin Periodontol[J]. J Clin Periodontol, 2014, 41(6):632-632.
[8]
Darveau R P, Belton C M, Reife R A, et al. Local chemokine paralysis, a novel pathogenic mechanism for Porphyromonas gingivalis[J]. Infection & Immunity, 1998, 66(4):1660-1665.
[9]
Johansson A. Aggregatibacter actinomycetemcomitans leukotoxin: a powerful tool with capacity to cause imbalance in the host inflammatory response[J].Toxins,2011,3(3):242-259.
[10]
Nibali L , Donos N , Farrell S , et al. Association between interleukin-6-174 polymorphism and Aggregatibacter actinomycetemcomitans in chronic periodontitis.[J]. J periodontol, 2010, 81(12):1814-1819.
[11]
Darveau R P. Periodontitis: a polymicrobial disruption of host homeostasis.[J]. Nat Revi Mic,2010,8(7):481-490.
[12]
Cekici A, Kantarci A, Hasturk H, et al. Inflammatory and immune pathways in the pathogenesis of periodontal disease[J]. Periodontology, 2014, 64(1):57-80.
[13]
Brower V. Controlling the inflammatory cascade[J]. Dental Abstracts, 2011, 56(3):164-165.
[14]
Araújo A A, Souza T O, Moura L M, et al. Effect of telmisartan on levels of IL-1, TNF-α, down-regulated COX-2, MMP-2, MMP-9 and RANKL/RANK in an experimental periodontitis model[J]. J Clin Periodontol, 2013, 40(12):1104-11.
[15]
Graves D T. The potential role of chemokines and inflammatory cytokines in periodontal disease progression[J]. Clin infec Dis, 1999, 28(3): 482-490.
[16]
Lane N, Armitage G C, Loomer P, et al. Bisphosphonate therapy improves the outcome of conventional periodontal treatment: results of a 12-month, randomized, placebo-controlled study[J]. J periodontol, 2005,76(7):1113-1122.
Issa J P, Ingraci d L C, Bg D S K, et al. The effect of simvastatin treatment on bone repair of femoral fracture in animal model.[J]. Growth Factors, 2015, 33(2):1-10.
[26]
Fracon R N, Teófilo J M, Moris I C, et al. Treatment with paracetamol, ketorolac or etoricoxib did not hinder alveolar bone healing: a histometric study in rats[J]. J Applied Oral Sci,2010,18(6):630-634.
[27]
Teófilo J M, Giovanini G S, Fracon R N, et al. Histometric study of alveolar bone healing in rats treated with the nonsteroidal anti-inflammatory drug nimesulide[J]. Implant dentistry, 2011, 20(2): e7-e13.
[28]
Brger U, Mühle T, Fourmousis L, et al. Effect of the NSAID flurbiprofen on remodelling after periodontal surgery[J]. J periodontal Res,1997,32(7):575-582.
[29]
Coimbra L S, Rossa Jr C, Guimaraes M R, et al. Influence of antiplatelet drugs in the pathogenesis of experimental periodontitis and periodontal repair in rats[J]. J periodontol, 2011, 82(5): 767-777.
[30]
Walters S M, Dubey V S, Jeffrey N R, et al. Antibiotic-induced Porphyromonas gingivalis LPS release and inhibition of LPS-stimulated cytokines by antimicrobial peptides[J]. Peptides, 2010, 31(9): 1649-1653.
[31]
Al-Khabbaz A K, Al-Shammari K F, Abdulaziz H, et al. Periodontal health of children with type 1 diabetes mellitus in Kuwait: a case-control study[J]. Medical Principles & Practice International Journal of the Kuwait University Health Science Centre, 2013, 22(2):144-149.
[32]
Mickels N, McManus C, Massaro J, et al. Clinical and microbial evaluation of a histatin-containing mouthrinse in humans with experimental gingivitis[J]. J Clin periodontol, 2001, 28(5): 404-410.
[33]
Beaumont P E, Mchugh B, Gwyer F E, et al. Cathelicidin host defence peptide augments clearance of pulmonary Pseudomonas aeruginosa infection by its influence on neutrophil function in vivo[J]. Plos One, 2014, 9(6):e99029-e99029.
[34]
Horibe K, Nakamichi Y, Uehara S, et al. Roles of cathelicidin-related antimicrobial peptide in murine osteoclastogenesis[J].Immunology,2013,140(3):344-351.
[35]
Rosenfeld Y, Papo N, Shai Y. Endotoxin (Lipopolysaccharide) Neutralization by Innate Immunity Host-Defense Peptides PEPTIDE PROPERTIES AND PLAUSIBLE MODES OF ACTION[J]. J Biologi Chemi,2006,281(3):1636-1643.
[36]
Scott M G, Vreugdenhil A E, Buurman W A, et al. Cutting edge: cationic antimicrobial peptides block the binding of lipopolysaccharide (LPS) to LPS binding protein[J]. J Immunol,2000,164(2):549-553.
[37]
Tew G N, Liu D, Chen B, et al. De novo design of biomimetic antimicrobial polymers[J]. Proceedings of the National Academy of Sciences, 2002, 99(8): 5110-5114.
2016, Vol. 27 
